5d 1m 3m 1y 5y 10y
Business Wire (Fri, 12:15PM)
Business Wire (Tue, 9:34AM)
Business Wire (Mar 3, 2014)
Business Wire (Feb 28, 2014)
at CNBC.com (Feb 27, 2014)
Business Wire (Feb 24, 2014)
Business Wire (Feb 24, 2014)
Business Wire (Feb 21, 2014)
at CNBC.com (Feb 18, 2014)
Business Wire (Feb 13, 2014)
at CNBC.com (Feb 6, 2014)
Business Wire (Feb 6, 2014)
at CNBC.com (Feb 5, 2014)
at CNBC.com (Jan 30, 2014)
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mLBusiness Wire (Jan 28, 2014)
at MarketWatch.com (Jan 21, 2014)
Marketwire (Jan 21, 2014)
Business Wire (Jan 21, 2014)
at CNBC.com (Jan 8, 2014)
at CNBC.com (Dec 30, 2013)
at CNBC.com (Dec 27, 2013)
at CNBC.com (Dec 27, 2013)
at CNBC.com (Dec 20, 2013)
TEVA vs. ETF Alternatives
Wednesday, Nov 272013, 1:46 PM
Wednesday, Nov 272013, 1:46 PM| Comment!
- Teva (TEVA -0.5%) gets an Orphan designation for Treanda in indolent B-cell non-Hodgkin lymphoma.
- TEVA also has six months of pediatric exclusivity for the drug.
- Summary of exclusivity for two indications: In iNHL, through April 2016; in CLL, through September 20, 2015. (PR)
- YTD U.S. sales (through Q3): $531M. Sales growth in Q3: +15%.
- Here's FierceBiotech's Eric Palmer on the impact of the news: "...extra sales of the orphan drug will not go very far toward offsetting the revenue hit TEVA will take when Copaxone goes off patent next year."
- See also: TEVA slams Copaxone sales forecast report.
Monday, Nov 252013, 4:49 AM
Monday, Nov 252013, 4:49 AM| Comment!
- Teva (TEVA) has downplayed a report that it expects profits from its multiple sclerosis treatment Copaxone will drop by 42% in 2014.
- Teva said a report in Israeli publication The Marker that provided forecasts for 2013-2018 "appears to be from an outdated presentation, is incomplete and does not reflect our full analysis."
- Teva intends to provide its 2014 outlook next month.
- Shares are -0.1% premarket.(PR)
Wednesday, Nov 202013, 3:15 PM
Wednesday, Nov 202013, 3:15 PM| 7 Comments
- Shares of Teva (TEVA +3.7%) are trading notably higher on the session.
- Helping the cause is Susquehanna, where analysts have upgraded the stock to Positive from Neutral.
- Price target is now $50 (from $43).
- Meanwhile, the rumor mill is alive with talk of a possible merger with either Mylan (MYL +0.8%) or Valeant (VRX +0.1%).
- "People are looking for the company to do something,” an S&P analyst quoted by Bloomberg says.
Monday, Nov 182013, 11:33 AM
Monday, Nov 182013, 11:33 AM| Comment!
- Teva (TEVA -0.6%) is out with an oncology portfolio update.
- Highlights: Lonquex was launched in Germany on November 4, Granix was launched in the U.S. on November 11, and the BLA for balugrastim has been withdrawn "pending the provision of additional confirmatory data." (PR)
- Although Goldman's Terence Flynn didn't "see balugrastim as a significant competitive threat to [Neulasta]," the analyst notes that "many investors did," and therefore, TEVA's move to pull the leukocyte growth factor from the FDA review process "removes a near-term competitive threat" for an Amgen (AMGN +1.9%) and also lifts "an overhang on shares heading into 2014."
- Goldman maintains a CL-Buy on AMGN.
- Price target is $140.
Thursday, Nov 142013, 4:31 PM
Monday, Nov 112013, 11:45 AM
Monday, Nov 112013, 11:45 AM| Comment!
- Teva Pharmaceutical (TEVA -0.5%) reaches an agreement to pay the State of Israel some $718M "for the release of trapped profits, settling tax assessments for the years 2005-2007, and applying similar principles through 2011."
- TEVA will take a charge of $235M in Q4.
- The deal "generates sources for dividends to shareholders ... and settles tax assessments which had been in dispute for a long time," the company says. (PR)
Friday, Nov 82013, 10:09 AM
Friday, Nov 82013, 10:09 AM| 2 Comments
- The risk-reward profile of Sanofi's (SNY -0.8%) MS treatment Lemtrada may not warrant approval, FDA staff says.
- Risks reportedly include "lifelong hypothyroidism, serious infusion reactions, melanoma and other malignancies, Graves’s ophthalmopathy and other autoimmune disorders, and prolonged increased susceptibility to infection." (full report)
- An Ad Com will take up the issue next Wednesday. The drug is approved in Europe.
- Down 70% on the news: CVRs ((GCVRZ)) on the drug.
- Competing relapsing MS treatments: Tecfidera and Tysabri (BIIB +1.1%) and Copaxone (TEVA +0.3%).
- For more, follow the discussion here on SA.
Tuesday, Nov 52013, 1:19 PM
Tuesday, Nov 52013, 1:19 PM| 1 Comment
- In an effort to avoid what it says will be "irreparable harm," Teva (TEVA -0.1%) has asked the U.S. Supreme Court to stay a lower court's ruling that would pave the way for generic Copaxone in early 2014.
- TEVA is prepping an appeal but wants a stay imposed in the mean time.
- Despite CEO problems and a political outcry tied to planned job cuts, some (like Barron's and Citi) think investors should look beyond the company's current problems and focus instead on the longer-term outlook.
Monday, Nov 42013, 9:45 AM
Monday, Nov 42013, 9:45 AM| Comment!
- Cell Therapeutics (CTIC +8.3%) initiated at Buy at Wainwright. Price target is $4.
- Evoke Pharma (EVOK +2.1%) initiated at Buy at Cantor. Price target is $19.
- MacroGenics (MGNX +0.8%) initiated at Leerink and BofA at Outperform and Neutral respectively. Price targets are $34 and $30.
- AstraZeneca (AZN +0.1%) cut to Neutral from Buy at UBS.
- WellCare Health Plans (WCG -0.6%) cut to Neutral from Buy at Monness Crespi.
- Teva (TEVA -0.9%) cut to Underweight from Neutral at JPMorgan. Price target to $38 from $43.
Friday, Nov 12013, 4:12 PM
Friday, Nov 12013, 4:12 PM| 1 Comment
- Universal Health Services (UHS) price target hiked to $70 from $75 on better-than-expected results from the company's acute care unit. (Q3 results)
- Acadia Healthcare (ACHC) price target raised to $47 (from $40) representing 29.5x analyst Jennifer Lynch's 2014 EPS estimate of $1.59.
- Teva (TEVA) price target cut to $44 from $49. Here's analyst David Maris on the CEO resignation: "Teva hosted a conference call where the chairman tried to calm investor fears with statements to the effect that ‘things have never looked better' and ‘if not for the black out period, I'd be tempted to buy the stock. With the stock ... having underperformed the S&P for the past one, three, and five years, many investors would argue the point and take him up on the offer.”
Thursday, Oct 312013, 8:52 AM
Thursday, Oct 312013, 8:52 AM| 2 Comments
- Teva Pharmaceutical (TEVA) manages to beat estimates for Q3 despite controversy over proposed job cuts and the CEO shakeup.
- Revenue for the period prints at $5.1B, up 2% Y/Y.
- Revenue growth by region: U.S., +4%; Europe, +4%; ROW, -8%.
- Global Copaxone sales rise 1% (flat ex-currency impact and -6% outside the U.S.).
- Revenue growth by product: Azilect, +21%; Nuvigil, -7%; Provigil, -58%; Treanda, +15%; ProAir, +3%; Qvar, +11%; Women's Health, +31%.
- Acting CEO Eyal Desheh says TEVA remains "committed to executing [the company's] strategy and diligently implementing changes [that] will ensure the growth of [the] business." (PR)
Thursday, Oct 312013, 8:32 AM
Wednesday, Oct 302013, 10:51 AM
Wednesday, Oct 302013, 10:51 AM| 2 Comments
- "We view this news as a significant setback ... as the company's recently implemented strategy to [get] back on a growth path, including recent accelerated cost reduction initiatives, could be called into question," Goldman's Jami Rubin says, regarding the resignation of Teva (TEVA -6.2%) chief Jeremy Levin.
- Rubin also says that "while investors have rewarded the heightened deal activity in the generic drug industry ... TEVA has not been moving quickly or aggressively enough to create shareholder value." This is reminiscent of Rubin's rationale for downgrading the shares back in July.
- Sell rating maintained.
- Price target is $40.
Wednesday, Oct 302013, 9:13 AM
Wednesday, Oct 302013, 6:54 AM
Wednesday, Oct 302013, 6:54 AM| 4 Comments
- Teva Pharmaceuticals's (TEVA) CEO Jeremy Levin has resigned just two days after the company denied a report that he was thinking of quitting due to a rift over strategy with Chairman Phillip Frost.
- Teva has appointed CFO Eyal Desheh as interim chief while it looks for a permanent successor to Levin.
- Teva's results are due out tomorrow.
- Shares are -4.4% premarket. (PR)
Monday, Oct 282013, 7:04 AM
Monday, Oct 282013, 7:04 AM| Comment!
- Teva (TEVA) has denied a report as "baseless" that CEO Jeremy Levin is considering retiring due to major differences of opinion with Chairman Phillip Frost and the board over implementing the company's new strategy.
- The report said that Teva's management has told the board to butt out of the day-to-day management of the company - although not quite in those words - which "has become common in recent months" and prevents the effective running of the firm.
- The report comes after Teva said earlier this month that it was slashing 5,000 jobs as it prepares for the end of Copaxone's patent protection, which could come next year. Shares are -1.6% premarket.